Agreed Skipper. Italy revenue is going to be non-existent for several years. And we have a dozen or so other countries already reimbursing with zero revenue to show for it.
However....one strategy they may be employing is to go "all-in" on the few bigger countries (UK, Spain, Italy), to show what Vazkepa can do. It probably makes little sense to have any staff in Sweden, Finland, Scotland, Netherlands, etc. where the target populations are in the 10's of thousands or low 100's of thousands.
But as with most things Amarin, they are not real clear on their strategy, other than just trying to get as many reimbursements in place as possible for a buyout. Because if they are NOT targeting a buyout soon, then I'm not sure why they are not selling any product in all these markets where they are already approved (and some have been approved for multiple years).
Market Data 
Markets 
AI
